Trial reportDrug design, development and therapy2026
Sugammadex for Neuromuscular Blockade Reversal and Postoperative Recovery in Laparoscopic Bariatric Surgery: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to evaluate the effect of sugammadex on the quality of postoperative recovery among patients undergoing laparoscopic bariatric surgery. Methods: In this randomized controlled trial, 60 patients scheduled for laparoscopic bariatric surgery were allocated to receive either neostigmine (N group) or sugammadex (S group) for neuromuscular blockade reversal. At the conclusion of surgery, the N group received intravenous neostigmine 0.04 mg/kg with atropine 0.02 mg/kg, while the S group received intravenous sugammadex 2 mg/kg. The primary outcome was the Quality of Recovery-15 (QoR-15) score at 24 hours postoperatively. Secondary outcomes included anesthesia recovery time, time to train-of-four (TOF) ratio ≥ 0.9, extubation time, time to achieve a modified Aldrete score ≥ 9, Richmond Agitation-Sedation Scale (RASS) scores, Visual Analogue Scale (VAS) pain scores after extubation, and time to first postoperative flatus/defecation. Results: QoR-15 scores at 24 hours postoperatively were significantly higher in the S group compared with the N group ( Conclusion: The sugammadex administration in patients undergoing laparoscopic bariatric surgery could expedite reversal of neuromuscular blockade, shorten anesthesia recovery time, and facilitate gastrointestinal function restoration. It also improved postoperative quality of recovery without elevating pain intensity or increasing opioid consumption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.